6 documents found, page 1 of 1
The Impact of Cholecystectomy in Patients with Post-Bariatric Surgery Hypoglycemia
Sardão, D; Santos-Sousa, H; Peleteiro, B; Resende, F; Costa-Pinho, A; Preto, J; Lima-da-Costa, E; Freitas, PBackground: Metabolic surgery is the foremost treatment for obesity and its associated medical conditions. Nonetheless, post-bariatric hypoglycemia (PBH) emerges as a prevalent complication. PBH pathophysiology implicates heightened insulin and glucagon-like peptide 1 (GLP-1) levels, with bile acids (BA) contributing to GLP-1 release. A plausible association exists between cholecystectomy and PBH, which is attr...
Beta Cell Function as a Baseline Predictor of Weight Loss After Bariatric Surgery
Borges-Canha, M; Neves, JS; Mendonça, F; Silva, MM; Costa, C; M Cabral, P; Guerreiro, V; Lourenço, R; Meira, P; Salazar, D; Ferreira, MJ; Pedro, JBackground: Obesity is a multifactorial disease, which is strongly associated to other metabolic disorders. Bariatric surgery is the most effective treatment of morbid obesity. The role of beta cell function in weight loss after bariatric surgery is uncertain. Aim: To evaluate the association between beta cell function and percentage of total body weight loss (TBWL%) 1, 2, 3, and 4 years after bariatric surgery...
Obesity and Cancer: the Profile of a Population who Underwent Bariatric Surgery
Brito, H; Santos, AC; Preto, J; Carvalho, D; Freitas, P.; Correia, Flora (CRIO Group)Introduction Obesity is a significant risk factor for cancer incidence and mortality. The number of patients with obesity who undergo bariatric surgery is increasing; however, the impact of such a procedure in affecting the risk of cancer is not completely understood yet. Methods We conducted a retrospective unicentric cohort study to characterize the occurrence of cancer in patients who underwent bariatric sur...
Erratum to “Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in...
Santos, AP; Vinagre, J; Soares, P; Claro, I; Sanches, AC; Gomes, L; Fernandes, I; Catarino, AL; Preto, J; Pereira, BD; Marques, AP; Rodrigues, FIn the article titled "Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism"[1], the affiliation for I. Claro was labeled incorrectly. The correct affiliation of the author I. Claro is Instituto Portugûes de Oncologia de Lisboa, Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal.
Gastroenteropancreatic neuroendocrine neoplasia characterization in portugal: R...
Santos, AP; Vinagre, J; Soares, P; Claro, I; Sanches, AC; Gomes, L; Fernandes, I; Catarino, AL; Preto, J; Pereira, BD; Marques, AP; Rodrigues, FBackground. The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has been increasing in the last five decades, but there is no large-scale data regarding these tumours in Portugal. We conducted a cross-sectional, multicentric study in main Portuguese centers to evaluate the clinical, pathological, and therapeutic profile of GEP-NENs. Methods. From November, 2012, to July, 2014, data from ...
Metabolic Score: Insights on the Development and Prediction of Remission of Met...
Faria, G; Pestana, D; Aral, M; Preto, J; Norberto, S; Calhau, C; Guimarães, JT; Taveira-Gomes, AINTRODUCTION: Metabolic syndrome (MetS) clusters the most dangerous cardiovascular disease risk factors. Although insulin resistance and central obesity play an important role in the pathogenesis, the factors that determine its development and ultimate remission after Roux-en-Y gastric bypass (RYGB) are not fully understood. METHODS: We recruited a prospective cohort of 210 consecutive patients after RYGB betwe...